Company Ainos, Inc.

Equities

AIMD

US00902F3038

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
1.04 ^USD	-1.89%		-4.59%	-49.27%

05-13	Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729	MT
03-19	Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	CI

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.

Number of employees: 46

USD in Million	2022	Weight	2023	Weight	Delta
Point-of-care Testing 100.0 %	4	100.0 %	0	100.0 %	-96.53%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	4	100.0 %	0	100.0 %	-96.53%

Managers	Title	Age	Since
Chun Hsien Tsai CEO	Chief Executive Officer	54	21-04-14
Lawrence Lin COO	Chief Operating Officer	55	21-07-31
Shu Ying Pan SAM	Sales & Marketing	-	-
Chih-Heng Lu PRN	Corporate Officer/Principal	44	21-08-10
Junyong Lee LAW	General Counsel	54	21-07-31

Members of the board	Title	Age	Since
Yao Chung Chiang BRD	Director/Board Member	70	21-04-14
Pao Sheng Wei BRD	Director/Board Member	66	22-06-14
Chung Yi Tsai BRD	Director/Board Member	47	21-04-14
Chung Jung Tsai BRD	Director/Board Member	52	21-04-14
Ting Chuan Lee BRD	Director/Board Member	40	21-04-14
Wen Han Chang BRD	Director/Board Member	60	21-04-14
Chun Hsien Tsai CEO	Chief Executive Officer	54	21-04-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,144,506	2,857,736 ( 46.51 %)	0	46.51 %

Name	Equities	%	Valuation
Ainos, Inc. (Cayman Islands) 41.25 %	2,456,319	41.25 %	3 M $
Chun Hsien Tsai 4.639 %	276,219	4.639 %	287 268 $
Stephen Chen 2.235 %	133,082	2.235 %	138 405 $
Wen Han Chang 1.785 %	106,265	1.785 %	110 516 $
Ting Chuan Lee 1.358 %	80,831	1.358 %	84 064 $
Chung Jung Tsai 1.212 %	72,186	1.212 %	75 073 $
Meng-Lin Sung 1.025 %	61,050	1.025 %	63 492 $
Yao Chung Chiang 0.9226 %	54,932	0.9226 %	57 129 $
Chung Yi Tsai 0.8890 %	52,932	0.8890 %	55 049 $
Pao Sheng Wei 0.8890 %	52,932	0.8890 %	55 049 $

Name	Equities	%	Valuation
CVI Holdings LLC -	82,500	-	5 363 $
Ayrton Capital LLC -	50,000	-	3 250 $
Citadel Securities GP LLC -	45,687	-	2 970 $
Hudson Bay Capital Management LP -	30,109	-	1 957 $
Boothbay Fund Management LLC -	25,000	-	1 625 $
Armistice Capital LLC -	25,000	-	1 625 $
Warberg Asset Management LLC -	18,800	-	1 222 $
UBS Securities LLC -	11,565	-	752 $
Clear Street LLC -	4,484	-	291 $

Ainos, Inc.

8880 Rio San Diego Drive Suite 800

92108, San Diego

+858 869 2986

http://www.ainos.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AINOS, INC.	-49.27%	6.51M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs